000			01560 a2200469 4500
005			20250517192311.0
264		0	_c20190219
008			201902s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/leu.2017.330 _2doi
040			_aNLM _beng _cNLM
100	1		_aPardanani, A
245	0	0	_aLong-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. _h[electronic resource]
260			_bLeukemia _c04 2018
300			_a1035-1038 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aBenzamides _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aJanus Kinase 1 _xantagonists & inhibitors
650	0	4	_aJanus Kinase 2 _xantagonists & inhibitors
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPrimary Myelofibrosis _xdrug therapy
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aThrombocytosis _xdrug therapy
700	1		_aGotlib, J
700	1		_aRoberts, A W
700	1		_aWadleigh, M
700	1		_aSirhan, S
700	1		_aKawashima, J
700	1		_aMaltzman, J A
700	1		_aShao, L
700	1		_aGupta, V
700	1		_aTefferi, A
773	0		_tLeukemia _gvol. 32 _gno. 4 _gp. 1035-1038
856	4	0	_uhttps://doi.org/10.1038/leu.2017.330 _zAvailable from publisher's website
999			_c27911036 _d27911036